^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Dupixent (dupilumab)

    i
    Other names: SAR231893, REGN-668, SAR-231893, REGN668
    Associations

    News

    Trials
    Company:
    Regeneron, Sanofi
    Drug class:
    IL-4Rα inhibitor
    Related drugs:
    Associations

    News

    Trials
    17h
    Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) (clinicaltrials.gov)
    P3, N=90, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Dupixent (dupilumab)
    17h
    Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (clinicaltrials.gov)
    P4, N=1324, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Dupixent (dupilumab)
    18h
    DUPLEX-AD: A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) (clinicaltrials.gov)
    P2, N=256, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Dupixent (dupilumab)
    2d
    A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers (clinicaltrials.gov)
    P1, N=180, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P1 trial
    |
    Dupixent (dupilumab)
    4d
    EpiBar: Effect of Dupilumab on nasal epithelial barrier function in patients with Chronic Rhinosinusitis with nasal polyps (CRSwNP) an exploratory pilot study (2023-509815-10-00)
    P4, N=80, Active, not recruiting, Medical University Of Vienna | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Dupixent (dupilumab)
    8d
    An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Apogee Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Dupixent (dupilumab)
    8d
    AIM4:Next Step: Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (clinicaltrials.gov)
    P4, N=250, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Dupixent (dupilumab)
    11d
    DIRECTION Study (2025-524495-39-00)
    P4, N=220, Not yet recruiting, Medical University Of Vienna
    New P4 trial • Real-world evidence
    |
    Dupixent (dupilumab)
    15d
    Inflammatory exacerbation of hepatic alveolar echinococcosis during dupilumab therapy: A case report. (PubMed, IDCases)
    Although causality cannot be established, inhibition of type 2 immune pathways may be associated with atypical inflammatory manifestations of latent helminth infections. Clinicians should remain vigilant for inflammatory presentations when prescribing biologic agents, particularly in endemic regions.
    Journal
    |
    IL13 (Interleukin 13) • IL4 (Interleukin 4)
    |
    Dupixent (dupilumab)
    21d
    DERMIND-AD: The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov)
    P=N/A, N=184, Recruiting, Sanofi
    New trial
    |
    Dupixent (dupilumab)
    21d
    A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=403, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IL13 (Interleukin 13)
    |
    Dupixent (dupilumab)
    22d
    A Phase 1 Study of GS101 Injection (clinicaltrials.gov)
    P1, N=294, Recruiting, Jiangsu Genscend Biopharmaceutical Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Dupixent (dupilumab)